Entero Therapeutics (NASDAQ:GRDX) Posts Earnings Results

Entero Therapeutics (NASDAQ:GRDX) released its quarterly earnings results on Wednesday. The company reported ($0.82) earnings per share for the quarter, FiscalAI reports. The firm had revenue of $0.04 million for the quarter.

Entero Therapeutics Price Performance

GRDX stock opened at $4.95 on Friday. Entero Therapeutics has a twelve month low of $1.06 and a twelve month high of $5.84. The firm has a market capitalization of $16.63 million, a P/E ratio of -2.93 and a beta of 1.38. The stock’s 50 day moving average is $2.81.

Hedge Funds Weigh In On Entero Therapeutics

A hedge fund recently bought a new stake in Entero Therapeutics stock. DRW Securities LLC acquired a new position in Entero Therapeutics, Inc. (NASDAQ:GRDX) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 48,623 shares of the company’s stock, valued at approximately $227,000. DRW Securities LLC owned 1.45% of Entero Therapeutics at the end of the most recent reporting period. 12.30% of the stock is owned by institutional investors and hedge funds.

About Entero Therapeutics

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company’s pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.